Literature DB >> 30121719

Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: a case series.

Saeed El Zein1, Jean El-Cheikh2, Aline El Zakhem1, Dima Ibrahim1, Ali Bazarbachi2, Souha S Kanj3.   

Abstract

PURPOSE: Mucormycosis (MCM) is a rare fungal infection affecting people with impaired immunity. Data related to MCM from Lebanon are scarce. The aim of this study is to shed light on the epidemiology, incidence, and outcome of patients with MCM hospitalized at a tertiary care center in Lebanon.
METHODS: We conducted a retrospective chart review between Jan 1, 2008 and Jan 10, 2018. All patients with proven or probable MCM were included.
RESULTS: A total of 20 patients were included. Their median age was 49 years and the majority were males. Comorbidities included mainly hematologic malignancy and diabetes mellitus. Most common sites of involvement were rhino-orbital and pulmonary, respectively. The number of MCM cases/10.000 hospital admissions increased significantly between 2008 and 2017 (0.47 vs. 1.18; P < 0.05). A liposomal amphotericin B formulation alone or in combination with other antifungals was used as a first line agent in all patients. All-cause mortality was 60%; however, death was attributed to MCM in 20% of cases.
CONCLUSION: The incidence of MCM has significantly increased over the past 10 years at our institution, most likely due to the increasing patient population at risk. Understanding the epidemiology of MCM in our setting would help guide antifungal therapy.

Entities:  

Keywords:  Epidemiology; Incidence; Lebanon; Mucormycosis

Mesh:

Substances:

Year:  2018        PMID: 30121719     DOI: 10.1007/s15010-018-1195-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

Review 1.  Mucormycosis in Iran: a systematic review.

Authors:  Afsane Vaezi; Maryam Moazeni; Mohammad Taghi Rahimi; Sybren de Hoog; Hamid Badali
Journal:  Mycoses       Date:  2016-02-15       Impact factor: 4.377

2.  Zygomycosis in the 1990s in a tertiary-care cancer center.

Authors:  D P Kontoyiannis; V C Wessel; G P Bodey; K V Rolston
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

3.  The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus.

Authors:  Arunaloke Chakrabarti; Ashim Das; Jharna Mandal; M R Shivaprakash; Varghese K George; Bansidhar Tarai; Pooja Rao; Naresh Panda; Subhash C Verma; Vinay Sakhuja
Journal:  Med Mycol       Date:  2006-06       Impact factor: 4.076

4.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

5.  Mucormycosis in the Eastern Mediterranean: a seasonal disease.

Authors:  M R Al-Ajam; A R Bizri; J Mokhbat; J Weedon; L Lutwick
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

Review 6.  Zygomycosis: conventional laboratory diagnosis.

Authors:  C Lass-Flörl
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

7.  Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis.

Authors:  R Y Chinn; R D Diamond
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

8.  Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis.

Authors:  Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2007-03-02       Impact factor: 9.079

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates.

Authors:  Jesús Guinea; Pilar Escribano; Antonio Vena; Patricia Muñoz; María Del Carmen Martínez-Jiménez; Belén Padilla; Emilio Bouza
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

View more
  7 in total

1.  Welcome to our new Section Editors in INFECTION.

Authors:  Johannes R Bogner
Journal:  Infection       Date:  2020-02       Impact factor: 3.553

Review 2.  Update on invasive fungal infections in the Middle Eastern and North African region.

Authors:  Marwan Osman; Aisha Al Bikai; Rayane Rafei; Hassan Mallat; Fouad Dabboussi; Monzer Hamze
Journal:  Braz J Microbiol       Date:  2020-07-05       Impact factor: 2.476

3.  Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Sameh S M Soliman; Yiyou Gu; Heewon H Jeon; Lina Zhang; Samuel W French; David A Stevens; John E Edwards; Scott G Filler; Priya Uppuluri; Ashraf S Ibrahim
Journal:  Sci Adv       Date:  2019-06-12       Impact factor: 14.136

Review 4.  Storm of a rare opportunistic life threatening mucormycosis among post COVID-19 patients: A tale of two pathogens.

Authors:  Mohan Bilikallahalli Sannathimmappa; Vinod Nambiar; Rajeev Aravindakshan
Journal:  Int J Crit Illn Inj Sci       Date:  2022-03-24

Review 5.  Mucormycosis co-infection in COVID-19 patients: An update.

Authors:  Abdullah S Alkhamiss; Ahmed A Ahmed; Zafar Rasheed; Ruqaih Alghsham; Ali Shariq; Thamir Alsaeed; Sami A Althwab; Suliman Alsagaby; Abdullah S M Aljohani; Fahad A Alhumaydhi; Sharifa K Alduraibi; Alaa K Alduraibi; Homaidan T Alhomaidan; Khaled S Allemailem; Raya A Alharbi; Samar A Alamro; Arwa M Alqusayer; Sahim A Alharbi; Thekra A Alharby; Mona S Almujaydil; Ayman M Mousa; Sultan A Alghaniam; Abdulrhman A Alghunaim; Rana Alghamdi; Nelson Fernández; Waleed Al Abdulmonem
Journal:  Open Life Sci       Date:  2022-08-10       Impact factor: 1.311

Review 6.  Epidemiology and Diagnosis of Mucormycosis: An Update.

Authors:  Anna Skiada; Ioannis Pavleas; Maria Drogari-Apiranthitou
Journal:  J Fungi (Basel)       Date:  2020-11-02

Review 7.  New insights on mucormycosis and its association with the COVID-19 pandemic.

Authors:  Mona G Alshahawey; Ghadir S El-Housseiny; Noha S Elsayed; Mohammad Y Alshahrani; Lamia Mel Wakeel; Khaled M Aboshanab
Journal:  Future Sci OA       Date:  2021-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.